TABLE 1.
Baseline and clinical characteristics of patients.
|
Overall (n = 461) n (%) or median (IQR or SD) |
PR + SD + PD (n = 388) n (%) or median (IQR or SD) |
CR (n = 73) n (%) or median (IQR or SD) |
p‐value | |
|---|---|---|---|---|
| Age (years) | 59.189 (11.754) | 59.577 (11.742) | 57.123 (11.682) | 0.103 |
| Gender | ||||
| Male | 313 (67.896%) | 266 (68.557%) | 47 (64.384%) | 0.573 |
| Female | 148 (32.104%) | 122 (31.443%) | 26 (35.616%) | |
| Smoking history | ||||
| Yes | 252 (54.664%) | 218 (56.186%) | 34 (46.575%) | 0.166 |
| No | 209 (45.336%) | 170 (43.814%) | 39 (53.425%) | |
| Pathological type | 0.221 | |||
| ADC | 237 (51.41%) | 204 (52.58%) | 33 (45.21%) | |
| SCC | 132 (28.63%) | 104 (26.8%) | 28 (38.36%) | |
| Others | 92 (19.96%) | 80 (20.62%) | 12 (16.44%) | |
| Clinical stages | 0.008* | |||
| III | 167 (36.226%) | 130 (33.505%) | 37 (50.685%) | |
| IV | 294 (63.774%) | 258 (66.495%) | 36 (49.315%) | |
| Differentiation | <0.001* | |||
| Well | 12 (2.6%) | 3 (0.77%) | 9 (12.33%) | |
| Moderate | 61 (13.23%) | 34 (8.76%) | 27 (36.99%) | |
| Poor | 128 (27.77%) | 102 (26.29%) | 26 (35.62%) | |
| Unknown | 260 (56.4%) | 249 (64.18%) | 11 (15.07%) | |
| Surgery | <0.001* | |||
| Yes | 101 (21.909%) | 59 (15.206%) | 42 (57.534%) | |
| No | 360 (78.091%) | 329 (84.794%) | 31 (42.466%) | |
| Radiotherapy | 0.556 | |||
| Yes | 34 (7.38%) | 27 (6.96%) | 7 (9.59%) | |
| No | 402 (87.20%) | 341 (87.89%) | 61 (83.56%) | |
| Unknown | 25 (5.42%) | 20 (5.15%) | 5 (6.85%) | |
| Laboratory tests | ||||
| Hemoglobin (g/L) | 129.542 (18.075) | 129.531 (18.313) | 129.603 (16.869) | 0.974 |
| Platelet (× 109/L) | 213.701 (84.957) | 215.822 (86.283) | 202.425 (77.098) | 0.184 |
| Leukocyte (× 109/L) | 7.331 (3.275) | 7.418 (3.395) | 6.873 (2.516) | 0.113 |
| Neutrophil (× 109/L) | 5.103 (2.875) | 5.202 (2.970) | 4.576 (2.249) | 0.041* |
| Lymphocyte (× 109/L) | 1.516 (0.568) | 1.497 (0.562) | 1.615 (0.589) | 0.115 |
| NLR | 3.881 (2.988) | 3.989 (3.045) | 3.307 (2.613) | 0.049* |
| PLR | 161.027 (94.062) | 164.059 (94.831) | 144.910 (88.752) | 0.097 |
| TP | 66.814 (6.095) | 66.665 (5.999) | 67.585 (6.561) | 0.269 |
| Albumin (g/L) | 38.773 (4.796) | 38.665 (4.800) | 39.338 (4.768) | 0.272 |
| Globulin (g/L) | 28.040 (4.888) | 28.001 (4.835) | 28.247 (5.187) | 0.708 |
| TBIL | 10.836 (4.991) | 10.989 (5.110) | 10.037 (4.265) | 0.094 |
| ALT | 26.843 (23.914) | 26.702 (23.734) | 27.575 (24.983) | 0.783 |
| AST | 24.803 (13.717) | 24.982 (14.088) | 23.877 (11.644) | 0.475 |
| Urea | 5.360 (2.048) | 5.381 (2.087) | 5.250 (1.842) | 0.588 |
| CRE | 74.112 (28.318) | 74.204 (30.101) | 73.632 (16.313) | 0.816 |
| LDH (U/L) | 208.134 (104.182) | 212.362 (109.431) | 186.056 (67.052) | 0.008* |
| CEA (ng/mL) | 5.170 [2.310, 20.005] | 5.455 [2.415, 21.945] | 4.190 [1.645, 8.065] | 0.022* |
| CYRF21‐1 (ng/mL) | 4.850 [2.958, 9.163] | 5.125 [3.118, 9.488] | 3.695 [2.480, 6.562] | 0.057 |
| Overall survival (month) | 16.000 [9.00, 29.000] | 15.000 [8.000, 26.000] | 27.000 [16.000, 43.000] | < 0.001* |
Abbreviations: ADC, adenocarcinoma; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CEA, carcino‐embryonic antigen; CR, complete response; CRE, creatinine; CYRF21‐1, cytokeratin fragment antigen 21‐1; LDH, lactate dehydrogenase; NLR, neutrophil‐to‐lymphocyte ratio; PD, progressive disease; PLR, platelet‐to‐lymphocyte ratio; PR, partial response; SCC, squamous cell carcinoma; SD, stable disease; TBIL, total bilirubin; TP, total protein.
*
p‐value < 0.05.